Infectious Disease
Adenovirus
1
Pipeline Programs↗
5
Active Trials↗
2
Companies Involved↗
Adenovirus is an early-stage landscape with 1 program across 2 companies. The most active players are Johnson & Johnson, Lokon Pharma AB.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
12
clinical trials
Completed5 · 42%
Recruiting2 · 17%
Unknown status1 · 8%
Not yet recruiting1 · 8%
Withdrawn1 · 8%
Active, not recruiting1 · 8%
Other1 · 8%
Clinical Trials
Trial Activity
12 trials
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
Active, not recruiting·—·Phase 1/2·NCT04364178·25 enrolled
Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT07150416·38 enrolled
Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects
Enrolling by invitation·—·Preclinical·NCT06027879·25 enrolled
Intranasal AD4-H5-VTN as an Adenovirus Vaccine
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01806909·51 enrolled
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04041570·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)